Fol­low­ing in­jec­tion side ef­fects, De­sign Ther­a­peu­tics to re­for­mu­late Friedre­ich's atax­ia drug, de­lay tri­al time­line

De­sign Ther­a­peu­tics said Tues­day morn­ing that it was plan­ning to re­for­mu­late its Friedre­ich’s atax­ia drug fol­low­ing in­jec­tion site re­ac­tions in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.